Physician Networks and the Complex Contagion of Clinical Treatment.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2019.18585
Abstract: One of the greatest challenges in contemporary research on quality of care is to understand unexplained regional variation in physicians’ use of new medical treatments. Keating et al1 offer valuable new insight into this problem… read more here.
Keywords: bevacizumab; treatment; keating al1; complex contagion ... See more keywords
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4465
Abstract: Importance Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. Objective To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab for… read more here.
Keywords: chemotherapy; metastatic colorectal; bevacizumab; colorectal cancer ... See more keywords
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Ophthalmology"
DOI: 10.1001/jamaophthalmol.2017.6565
Abstract: Importance Prevalence of persistent central-involved diabetic macular edema (DME) through 24 weeks of anti–vascular endothelial growth factor therapy and its longer-term outcomes may be relevant to treatment. Objective To assess outcomes of DME persisting at… read more here.
Keywords: bevacizumab ranibizumab; bevacizumab; persistent dme; aflibercept bevacizumab ... See more keywords
Analysis of Anti-Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2019.1971
Abstract: Importance The frequency of anti-vascular endothelial growth factor (VEGF) injections has grown exponentially with the introduction of bevacizumab, ranibizumab, and most recently aflibercept. The cost associated with these medications has garnered significant national attention, warranting… read more here.
Keywords: part beneficiaries; bevacizumab; part; 2012 2015 ... See more keywords
Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2019.5132
Abstract: Importance Radiation retinopathy following plaque radiotherapy for uveal melanoma can lead to vision loss that might be avoided with prophylactic anti-vascular endothelial growth factor treatment. Objective To determine visual outcome following prophylactic intravitreal bevacizumab in… read more here.
Keywords: prophylactic intravitreal; bevacizumab; uveal melanoma; intravitreal bevacizumab ... See more keywords
Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2022.0030
Abstract: Importance Intravitreal bevacizumab effectively treats severe retinopathy of prematurity (ROP), but it enters the bloodstream and may reduce serum vascular endothelial growth factor (VEGF), potentially causing detrimental effects on developing organs in the premature infant.… read more here.
Keywords: bevacizumab; treatment; injection; plasma vegf ... See more keywords
Investigation of drugs affecting hypertension in bevacizumab‐treated patients and examination of the impact on the therapeutic effect
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3587
Abstract: In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic efficacy. However, it is not clear whether drugs that control blood pressure influence bevacizumab's efficacy. In this study, we investigated drugs that may… read more here.
Keywords: bevacizumab; impact therapeutic; hypertension bevacizumab; bevacizumab treated ... See more keywords
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6135
Abstract: INTRODUCTION Cisplatin plus pemetrexed followed by pemetrexed is an efficacious platinum combination regimen for advanced non-squamous, non-small cell lung cancer (NSCLC). Data regarding the addition of bevacizumab, especially in maintenance treatment, are insufficient. METHODS Eligibility… read more here.
Keywords: pemetrexed alone; pemetrexed bevacizumab; group; non squamous ... See more keywords
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30838
Abstract: BACKGROUND Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit. An early indicator of efficacy or futility may allow early discontinuation for nonresponders. This study… read more here.
Keywords: recurrent glioblastoma; magnetic resonance; bevacizumab; resonance imaging ... See more keywords
A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32340
Abstract: Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The Src family kinase inhibitor dasatinib has been found to effectively block bevacizumab‐induced glioma invasion in preclinical models, which… read more here.
Keywords: bevacizumab; placebo controlled; randomized placebo; phase randomized ... See more keywords
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32163
Abstract: We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme‐linked immunosorbent assay (ELISA). Correlations between… read more here.
Keywords: soluble carbonic; carbonic anhydrase; bevacizumab; efficacy bevacizumab ... See more keywords